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The potentially detrimental effects of cancer and related
treatments on cognitive functioning are emerging as a key fo-
cus of cancer survivorship research. Many patients with cen-
tral nervous system (CNS) or non-CNS tumours develop
cognitive problems during the course of their disease that
can result in diminished functional independence and can
continue well into the survivorship period.
In recent years, growing attention is being paid to the po-
tential adverse effects of chemotherapy on brain and cogni-
tive function. This central neurotoxicity may manifest as
both acute and delayed complications. Virtually all categories
of chemotherapeutic agent have been associated with ad-
verse neurological effects, including both acute and chronic
encephalopathy. More subtle cognitive dysfunction has also
been demonstrated and frequently manifests as diminished
memory, executive function, attention and information pro-
cessing speed.
In this article on chemotherapy and cognitive functioning
we will summarise knowledge on the incidence of cognitive
deficits, the neuropsychological pattern and structural brain
changes associated with chemotherapy, risk factors identified
for developing neurotoxicity and underlying mechanisms as
well as current treatment options to prevent or diminish the
adverse effects of chemotherapy on cognition.
We will focus on chemotherapy-associated cognitive
problems in breast cancer patients, as these symptoms
have been particularly well studied in this patient group.
In addition, studies on chemotherapy and cognition in
adult CNS cancer patients will also be discussed. In this
group of patients chemotherapy may be associated with
stabilisation or improvement of cognitive function due to
better disease control, but may at the same time go hand
in hand with CNS toxicity as a consequence of
chemotherapy.2. Neuropsychological studies in breast cancer
patients
Over the last 10–15 years, increasing evidence has revealed
the occurrence of acute and long-term cognitive problems
for a subset of patients following chemotherapy applied in
the treatment of non-CNS malignancies. In breast cancer pa-
tients alone, over 60 neuropsychological studies have been
published that have investigated whether adjuvant chemo-
therapy is associated with cognitive impairment [1–3]. In the
early years most of these studies had a cross-sectional design
and provided us with a snapshot of the prevalence of cogni-
tive impairment and the characteristics associated with this
impairment at specific moments post-chemotherapy. In re-
cent years, prospective neuropsychological studies on the
incidence of cognitive problems arising from pre- to post-che-
motherapy supported the previous observed relationship be-
tween chemotherapy exposure and cognitive problems by
demonstrating cognitive decline post-treatment relative to
pre-treatment cognitive performance.
Thoseprospective studieswithapre-treatmentassessment
also indicated the importance of a baselinemeasure, as several
studies observed lower than expected cognitive performance
in breast cancer patientswhoare about to undergo chemother-
apy in comparison to reference data of non-cancer subjects or
cancer patients with lower disease stages who will not need
chemotherapy. Up till now, no explanation has been found
for thesedecreasedcognitive scoresat baseline. Surgery (under
general anaesthesia), distress, fatigue or disease-associated
immune responses cannot yet clarify this observation.
3. Frequency and pattern of cognitive
dysfunction
The vast majority (70%) of the neuropsychological studies
demonstrated cognitive impairment and/or cognitive declinesmanlaan
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cytotoxic agents compared to breast cancer patients without
chemotherapy or compared to non-cancer controls, regard-
less of the design of the study.
Patients show deficits on a wide range of standardised
neuropsychological tests, but core impairments are related
to learning new information and accelerated forgetting of
information. Impairment in executive functions – such as
planning and implementing strategies, flexible shifting and
working memory – is also common, as are deficits in psycho-
motor speed (indicative of a frontal–subcortical profile).
Despite the accumulation of knowledge on the cognitive
side-effects of chemotherapy, the actual incidence of this
impairment is still a subject of research. Estimates of affected
patients vary from 17% to 78% across studies, because of dif-
ferences between treatment regimens and between individ-
ual patients, but also owing to variations in study measures,
assessment times and criteria applied to define cognitive
impairment and deterioration. When the magnitude of the
cognitive deficits as expressed in sizes of effects is studied,
a large variation between studies is also observed.
4. Course over time
The literature has shown that cognitive changes can arise
during treatment and can persist up to several years after
completion of treatment. Studies have largely followed pa-
tients up to 1–2 years post-treatment. Only a few studies have
investigated the very late (i.e. P5 years post-treatment) ef-
fects of chemotherapy, but those that have show long-term
cognitive problems in chemotherapy-exposed breast cancer
survivors. A recent large study showed that breast cancer sur-
vivors who received CMF chemotherapy (cyclophosphamide,
methotrexate, 5-fluorouracil) on average 20 years previously
were more likely to have lower performance on memory,
information processing speed and psychomotor speed com-
pared with women without a history of cancer. The magni-
tude of the effects was comparable to approximately 6 years
of age-related decline in cognitive function [4].
The influence of cancer and cancer treatment on the pro-
cess of cognitive ageing is a topic that is increasingly receiv-
ing attention. There is concern that chemotherapy may
induce accelerated ageing and that it can increase an individ-
ual’s susceptibility to late-emerging cognitive decline or
dementia. The underlying development of cognitive impair-
ment in ageing appears to begin at mid-life. Genetic signa-
tures of brain ageing (i.e. from transcriptional profiling in
post-mortem brains) can be identified in subjects as early as
their 40s. Substantial evidence demonstrates that a wide vari-
ety of variables in early life are determinants of cognition in
later life. Furthermore, both lifestyle and health-related risk
factors in mid-life are associated with poor cognition decades
later. It is plausible that damage to brain health in young to
middle-aged women becomes even more clinically evident
many years later when the brain is extra vulnerable. There-
fore it is essential to investigate how chemotherapy in earlier
life may influence cognition in later life.
Different trajectories for chemotherapy-associated cogni-
tive problems have been proposed in the literature. It couldbe that long-term cognitive problems result from lack of
recovery from the acute effects of treatment. It could also
be that the initial effect of treatment may produce a cascade
of biological events that cause continued cognitive decline
with ageing. Alternatively, chemotherapy may not be suffi-
cient to cause enough redundancy loss to immediately affect
cognitive function, but may produce a delayed effect as age-
ing continues, with the slope of change being influenced by
a variety of factors [5].
Prospective studies with a very long-term follow-up or
studies focusing on older cancer survivors are almost ab-
sent. A study on the effects of chemotherapy and cognition
in patients P65 years of age showed that these subjects
experienced more cognitive decline than unexposed coun-
terparts. Incidence of dementia was not explored in this
study, and even though these subjects were of older age,
their mean time since treatment was still relatively short
[6,7]. A few retrospective studies have been published
examining the risk of dementia in breast cancer survivors
up to 15 years after completion of cytotoxic treatment;
these studies used data from the linked Surveillance, Epide-
miology and End Results (SEER)–Medicare database. None of
these studies showed any clear evidence for the existence
of such a relationship, although several methodological is-
sues limit the validity and interpretation of the studies [8–
11].
5. Risk factors
Several factors have been identified that generally increase
the risk of developing neurotoxicity associated with chemo-
therapy. These include: (1) exposure to higher doses due to
planned use of high-dose regimens, or to high concentrations
of the parent drug and/or its metabolite due to impaired sys-
temic clearance and/or pharmacogenetic modulation of drug
pharmacokinetics; (2) additive or synergistic effects of multi-
agent chemotherapy; (3) additive or synergistic effect of mul-
timodality therapy that includes administration of chemo-
therapy either concurrently with or subsequently to cerebral
radiation; (4) intra-arterial administration with blood–brain
barrier disruption; and (5) intrathecal administration [12–17].
From the literature it is clear that not all patients are af-
fected equally by chemotherapy. The finding that a subgroup
of patients experience persistent post-treatment cognitive de-
cline has led to the examination of patient- and disease-re-
lated risk factors for cognitive change. Candidate predictors
of cognitive dysfunction frequently studied include age, edu-
cation and pre-morbid IQ; however, no consistent predictors
have been identified. Most studies failed to identify a relation-
ship between treatment-related cognitive decline and age, IQ,
education, baseline cognitive function and a host of other fac-
tors such as depression, anxiety, stress, fatigue, disease stage,
haemoglobin levels and treatment-induced menopause.
When an association between a sociodemographic or clinical
predictor and cognitive dysfunction has been found the rela-
tionship is generally weak [3]. However, given the small sam-
ple sizes in nearly all studies, exploration of any
sociodemographic or clinical predictors is likely to be
underpowered. This is also the case for genetic factors (e.g.
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been examined as potential risk factors for cognitive
decline [5].
Risk factors – endocrine treatment: a treatment-related risk
factor for cognitive decline in breast cancer patients that is
of particular clinical relevance is the combined use of endo-
crine therapy. Breast cancer patients undergoing chemother-
apy often receive endocrine therapy as well. These therapies
commonly consist of treatment with selective oestrogen
receptor modulators (SERMs) such as tamoxifen and/or aro-
matase inhibitors (AIs) such as exemestane, anastrozole or
letrozole. Evidence derived from basic as well as clinical re-
search indicates that estradiol, within a time window of
opportunity, can stimulate neuroplasticity in brain areas in-
volved in cognitive behaviour leading to improved perfor-
mance [18–20]. Since SERMs and AIs also target brain areas
involved in the regulation of cognitive behaviour, it is plausi-
ble that these substances may contribute to cognitive deteri-
oration in breast cancer patients. Blocking estradiol synthesis
with AIs deprives the brain of modulation via estradiol and
therefore theoretically results in decreased neuroplasticity
and impaired cognitive functioning. However, surprisingly,
studies in breast cancer patients seem generally to indicate
that AIs less consistently adversely influence cognitive func-
tioning compared with SERMs [21]. Studies specifically
addressing the interaction between chemotherapy and endo-
crine therapy are sparse and the majority of studies have
been too small to adequately investigate this interaction. Ab-
sence of oestrogen neuroprotective action in the brain – in the
natural, surgical or chemotherapy-induced postmenopausal
brain – makes the brain possibly extra vulnerable to neural
damage by chemotherapy [22].
Particularly in older breast cancer patients, treatment with
SERMs seems to have a potentially detrimental effect on cog-
nitive functioning [23]. Basic research is rather conclusive on
the neuroprotective properties of SERMs in the absence of cir-
culating estradiol, but the effects of chronic SERM administra-
tion on cognitive behaviour are more ambiguous. Cleary more
research is needed, particularly on the effects of SERMs on the
brain and behaviour in relation to age and the length of depri-
vation of endogenous estradiol.
Risk factors – information: information on chemotherapy-
associated cognitive problems is more and more accessible
to patients. The reporting of cognitive problems may also be
influenced by strictly cognitive mechanisms that are not
rooted in psychological distress or negative affect, but simply
in the extent to which a patient is informed about the possi-
bility of cognitive problems following chemotherapy. Several
studies on cognitive deficits in breast cancer patients showed
that mere information about the association between chemo-
therapy and cognitive problems resulted in lower memory
performance and higher complaint reporting [24,25]. These
effects occurred independently of negative affect and pre-
existing knowledge. The notion that mere information can
add to the occurrence andmaintenance of cognitive problems
is derived from a large body of social psychological research
on stereotype threat and priming. Stereotype threat – i.e. fear
of confirming a stereotype – has been researched extensively,
and evidence shows that activation of a stereotype or schemaunconsciously leads to behaviour that is in correspondence
with that stereotype [26,27].
Concepts of stereotype threat and priming are important
for explaining the effects of treatment-related information
on complaint reporting and neuropsychological test scores.
Furthermore, it may be that some individuals are particularly
vulnerable to these effects. Research shows that stereotype
threat effects are stronger among people who are especially
cognizant of the particular stigma, and that participants
who self-identify more strongly with a stereotyped group
show stronger stereotype threat effects on cognitive function
[28]. A recent study showed that receipt of stereotypical infor-
mation about the occurrence of medical problems experi-
enced by cancer patients primed the cognitive accessibility
of the cancer patient stereotype and differentially affected
women’s cognitive complaints and test scores, depending
on their level of consciousness of cancer patient stigma [29].
It is not suggested that these psychological processes
should be viewed as alternative explanations for biological
influences. Rather, the possibility is raised that, for certain pa-
tients, self-regulatory and expectancy processes may also
play a role – as a contributing, additive or meditational influ-
ence – in cognitive functioning. The next steps for clinical
practice include the determination of the severity and dura-
tion of priming effects and to further understand the individ-
ual variation in these effects. In addition there is a need to
explore the possibilities of diminishing or preventing these
effects.6. Neuropsychological studies in patients
with central nervous system tumours
Evaluating adverse effects of chemotherapy on cognitive
function in CNS cancer patients is often challenging because
of the variety of other factors that can impact cognition in
this population, most notably treatment with radiation and
tumour progression. Both radiation and chemotherapy have
been reported to share at least one common mechanism for
their adverse effect on brain and cognition: disruption of
the neural stem and precursor cell function [30]. Only recently
clinical trials have incorporated cognitive testing into their
study design, providing the opportunity to address these is-
sues in large samples of homogeneously treated patients.
Radiation therapy has been demonstrated to adversely im-
pact brain and cognition through vascular damage and
inflammation, and via damage to neuronal progenitor cells
affecting hippocampal neurogenesis and oligodendroglial for-
mation [31]. Impairment in processing speed, attention, exec-
utive function and memory is commonly seen in brain
tumour survivors previously treated with radiation therapy
[32]. Several recent retrospective studies have examined the
effects of radiation dose on different areas of the brain and
cognitive outcomes. These studies provide evidence of a
dose–response relationship between radiation to the bilateral
hippocampal region and memory function [33], in addition to
other brain regions and more heterogeneous cognitive out-
comes [34]. Trials are currently under way in many centers
to explore the use of technological advances in radiation
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to explore different forms of radiation such as proton therapy
that may similarly achieve reduced-dose exposure to the nor-
mal brain and other critical structures.
The standard of care for glioblastoma patients has in-
cluded concomitant chemoradiation and adjuvant chemo-
therapy with temozolomide since 2004 [35]. A small single-
institution study with standard-dose temozolomide reported
cognitive decline in three out of 13 progression-free patients
after concurrent chemoradiation and three cycles of adjuvant
chemotherapy [36]. Declines were evident in psychomotor
speed, attention and executive function, but not in verbal
memory or working memory span. The results of a larger
multi-institutional cooperative group trial comparing adju-
vant standard-dose temozolomide and dose-dense temozolo-
mide have also been reported [37]. In patients that were
clinically and radiographically progression-free after concur-
rent chemoradiation and three cycles of adjuvant chemother-
apy, 30% demonstrated cognitive decline, with no differences
between arms. Cognitive decline was evident in all domains
assessed – including verbal learning and memory, executive
function and processing speed – and was prognostic of pro-
gression-free and overall survival. A recent study using tem-
ozolomide-administered rodents has demonstrated reduced
hippocampal neurogenesis, decreased theta activity as mea-
sured by electromyography during an eye blink conditioning
task and disrupted learning [38].
Due to the importance of angiogenesis in the growth and
spread of cancer, there has been a great interest in inhibitors
of vascular endothelial growth factor (VEGF), such as bev-
acizumab. Anti-VEGF agents have been demonstrated to pro-
duce rapid radiological improvement, ostensibly due to their
ability to reduce tumour and blood–brain barrier permeability
associated with leaky blood vessels. There is concern that this
represents a ‘pseudoresponse’ which complicates the inter-
pretation of traditional imaging end-points [39]. A phase II
non-comparative study of bevacizumab in a recurrent glio-
blastoma multiforme (GBM) population included tests of cog-
nition to characterise changes in brain function associated
with bevacizumab therapy. In patients who achieved an
objective radiographic response or who were clinically and
radiographically progression-free at 24 weeks, the majority
(75% and 70%, respectively) demonstrated stable or improved
cognitive function relative to their pretreatment baseline [40].
Two placebo-controlled phase III trials with cognitive end-
points in newly diagnosed GBM patients are currently under
way and will provide more information on the impact of bev-
acizumab on cognitive function.
The long-term outcomes and associated reanalysis from
the RTOG 9402 trial recently reported [41] a doubling of overall
survival rates in pure or mixed anaplastic oligodendroglioma
patients with 1p/19q co-deletion who received procarbazine,
CCNU and vincristine (PCV) chemotherapy. This trial did not
assess patient-oriented outcomes such as cognitive function
to help determine the net clinical benefit of this survival
advantage. However, two single-institution studies assessed
cognition in anaplastic glioma [42] and GBM [43] patients trea-
ted with regimens that included PCV. Of patients with ana-
plastic glioma, 35% who were re-evaluated at a median of
8 months after initiation of treatment demonstrated cognitivedecline. In GBM patients retested at a mean of approximately
8 months after initiating treatment, decreased cognitive func-
tion (in 44–52% of patients) was most commonly observed in
the domains of psychomotor speed, executive function and
memory. Unfortunately, these studies were not designed to
distinguish the effects of chemoradiation from adjuvant che-
motherapy and did not control for tumour progression, com-
plicating the interpretation of these results as evidence of
chemotherapy-related neurotoxicities.
Cognitive dysfunction is a frequent presenting/occurring
sign in patients with primary CNS lymphoma (PCNSL). How-
ever, unlike patients with primary brain tumours, many
PCNSL patients who receive chemotherapy with or without
radiation therapy show evidence of improvement in cogni-
tive function [44]. For example, Correa et al [45] reported
improvements in executive function and verbal memory up
to 2 years after treatment in newly diagnosed PCNSL pa-
tients who were treated with induction rituximab, metho-
trexate, procarbazine and vincristine followed by reduced-
dose whole-brain radiation and consolidation high-dose
cytarabine.
7. Neural substrate and underlying
mechanisms
Despite evidence of cognitive changes associated with che-
motherapy in cancer patients, the pathophysiology of these
changes needs further elucidation.
Neuroimaging studies in breast cancer patients indicate
structural changes in the brain associated with certain che-
motherapeutic agents, and have started to shed light on the
brain alterations that may be part of the mechanisms under-
lying the observed cognitive dysfunction in patients following
administration of chemotherapeutic compounds without tar-
geted CNS delivery.
8. Imaging studies
Several structural imaging studies have been conducted
among breast cancer patients treated with adjuvant regi-
mens, with assessments generally occurring from months
to 3 years after completion of treatment [46–50], although
two studies examined patients 10 and 20 years after comple-
tion of treatment [51,52]. Nearly all of these studies are indic-
ative of structural brain differences between patients that
received chemotherapy and either healthy controls or breast
cancer controls that did not receive chemotherapy. White-
matter pathology has been observed within months up to
10 years post-treatment, after both high-dose and standard-
dose regimens. Studies using voxel-based morphometry have
reported volume reductions in white and grey matter 1 year to
20 years after completion of chemotherapy. A prospective
study observed focal grey matter volume decrease 1 month
after the cessation of chemotherapy, which recovered in some
but not all regions at 1 year post-treatment.
The cerebral white matter seems particularly vulnerable to
the effects of chemotherapy. Studies investigating cerebral
white matter integrity using diffusion tensor imaging (DTI) re-
ported lower fractional anisotropy (FA) in the genu of the cor-
pus callosum, lower FA in frontal and temporal white matter
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cancer patients who received standard-dose anthracycline-
based regimens compared with breast cancer controls and
healthy controls. In a study conducted 10 years after comple-
tion of high-dose chemotherapy, DTI also showed lower FA in
several white-matter tracts compared with breast cancer pa-
tients who never received chemotherapy [53]. In a large study
conducted on average 20 years after completion of treatment,
it was shown that in the absence of significant group differ-
ences in white matter integrity, time since treatment was in-
versely associated with lower global and focal white matter
integrity within the breast cancer group [54]. This cross-sec-
tional indication of affected white matter integrity was sup-
ported by a prospective study showing that breast cancer
patients who received chemotherapy displayed significant de-
creases in FA in frontal, parietal and occipital white-matter
tracts from pre- to post-chemotherapy, whereas for both a
healthy control and a breast cancer control group, FA values
were the same between baseline and follow-up [55].
Moreover there seems to be a link between the abnormal
microstructural properties in white-matter regions and the
cognitive impairments seen in breast cancer patients treated
with chemotherapeutic agents; several studies observed cor-
relations between abnormal diffusion properties and cogni-
tive problems on neuropsychological testing [53].
The observed changes in DTI parameters may be related to
demyelination of white matter axons or axonal injury after
chemotherapy. Although caution is warranted in directly
translating changes on structural imaging measures into bio-
logical changes, a rapidly increasing number of preclinical
animal studies are helping define potential mechanisms
underlying chemotherapy-induced cognitive dysfunction,
and their results relate to a significant extent to the observa-
tions in human studies.
9. Animal studies
Valuable insights have come from preclinical studies on the
potential pathogenic mechanisms involved in cognitive
impairment related to systemic administration of chemother-
apeutic compounds without targeted CNS delivery, although
the precise mechanisms remain insufficiently understood.
Many factors have been proposed to play a role in chemother-
apy-induced neurotoxicity, including the directly toxic effects
of chemotherapeutic agents on various brain cells, vascular
injury and the indirect immune-mediated inflammatory pro-
cesses. It is unlikely that a single mechanism can explain
much of the major cognitive problems observed in cancer pa-
tients following chemotherapy.
Experimental studies have shown that many chemothera-
peutic agents, when administered peripherally and in clini-
cally relevant dosages, are associated with adverse effects
on neurobiology and cognition (including 5-fluorouracil,
methotrexate, doxorubicin, paclitaxel, cisplatin, BCNU and
cyclophosphamide). In behavioural studies in animals, che-
motherapy-related deficits have been observed in rodents
on tasks that require involvement of the hippocampus and
frontal systems. Toxicity is observed in multiple CNS cell
types and multiple CNS regions [56]. Specifically, chemother-apy-induced damage of mature post-mitotic oligodendrocytes
and immature progenitor cell populations required for ongo-
ing neurogenesis, gliogenesis and maintenance of white mat-
ter integrity seems to be an important aetiological factor in
the development of neurotoxicity [57].
Research focusing on the development of strategies to in-
hibit specific transporters to enable drugs to cross the blood–
brain barrier (BBB) in sufficient amounts is also relevant for
understanding the mechanisms by which chemotherapeutic
agents not targeted to reach the CNS cause cognitive and
brain changes. Gong et al. [58] propose in their stem-cell
hypothesis that differential sensitivities of glioma stem cells
and neural stem cells to alkylating agents, temozolomide, cis-
platin and targeted agents such as erlotinib and bortezomib
hold the key to the resistance of primary brain tumours and
the occurrence of chemotherapy-associated neurotoxicity in
non-CNS disease.
The development of modalities that enhance delivery of
drugs to brain tumours will also increase the drug exposure
of the normal brain tissue, and may place patients at risk
for treatment-induced cognitive decline. Until now, several
preclinical studies have investigated pharmacological preven-
tion strategies that further underscore the relevance of sev-
eral hypothesised mechanistic pathways underlying the
effects of chemotherapeutic agents on the brain and behav-
iour. Konat et al. [59] showed that N-acetyl cysteine, an anti-
oxidant, ameliorated cognitive impairment in Wistar rats
after combined administration of cyclophosphamide and
doxorubicin. Two recent studies further explored potential
candidates for interventions. A study by Lyons et al. [60] dem-
onstrates that fluoxetine, when administered before and dur-
ing treatment with 5-FU in rats, may prevent cognitive
impairment and the loss of normal cell proliferation in the
hippocampus observed after administration of 5-FU. Vijaya-
nathan et al. [61] demonstrated that treatment with a gluta-
mate receptor antagonist improved cognition after
intrathecal administration of methotrexate in rats.
10. Interventions
Cognitive dysfunction is a common consequence for many
cancer patients, and it does not always fade away. As indi-
cated, pharmacological interventions to prevent or intervene
against cognitive symptoms are in an early stage of develop-
ment. Agents that have been examined or that are currently
under investigation in patients include erythropoietin, meth-
ylphenidate, modafinil, donepezil and melatonin [62,63].
Some of these agents are promising, but the need for their rig-
orous testing with appropriate study designs and sufficient
sample sizes precludes translation and implementation in
daily practice.
Within the area of neuropsychological rehabilitation
roughly two models can be distinguished: the restoration
model and the compensation model [64]. The restoration
model is directed at restoring damaged cognitive functions
through function training, often using a so-called repeated
practice approach, based on the assumption that specific
stimulation induces plasticity. But evidence is still lacking
that the benefits of training on specific tasks will transfer to
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the level of cognitive functioning. Compensation techniques,
on the contrary, are proven to be successful. Improvement in
daily life functioning can be achieved using intact cognitive
abilities and strategies. Neuropsychological rehabilitation
based on the compensation model together with psycho-edu-
cation and coping strategies can be offered to cancer patients
confronted with cognitive problems to maximise their ability
to function [65].11. Conclusion
Evidently, people with (a history of) cancer constitute an
increasing group in our community. From this viewpoint,
we have an obligation to obtain information on the cognitive
effects of chemotherapy from a descriptive and preventive
standpoint, and from an individual as well as a societal per-
spective. Chemotherapy is a necessary component in the
management of many types of cancer, and the choices be-
tween different regimens in terms of adequate cancer control
and minimal side-effects are restricted. Many cancer patients
are returning to employment or other activities that may be
affected by cognitive functioning. It is critical to identify cog-
nitive effects of cancer treatment, to explore the mechanisms
underlying these cognitive effects and to explore possible
interventions that follow from these mechanisms and that
may minimise cognitive side-effects and their severity and
impact.
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